Faron H1 operating loss narrows to EUR 11.1 million; loss per share improves to EUR 0.06 in FY26 H1

• Faron Pharmaceuticals posted an IFRS operating loss of EUR 11.1 million for January–June 2026, narrowing 6.16% year over year.
• IFRS loss per share improved to EUR 0.06 from EUR 0.18 in the year-ago period.
• R&D expenses rose 7.01% to EUR 7.59 million, while general and administrative costs fell 25.89% to EUR 3.51 million.
• Cash and cash equivalents climbed to EUR 32 million at June 30, 2026, while equity swung to EUR 11.56 million from a year-ago deficit.
• Management flagged plans to start the randomized Phase 2b BEXERA trial in higher-risk MDS in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.